If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
Receive an email update when we add a new PRECISION MEDICINE article.
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- The KEYNOTE-024 Precedent for Advanced-NSCLC Treatment on November 16, 2018 at 8:23 am
2018 1.0 Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer Care Nov 30, 2018 1.0 […]
- Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of on November 14, 2018 at 6:00 am
The third poster will share results of a study on medical oncologists' knowledge, awareness and perceptions of precision medicine and liquid biopsy biomarker testing specific to breast cancer and ESR1 ... […]
- Helomics Corp Partners with UK 100,000 Genomes Project to Drive its Artificial Intelligence-Powered Precision Oncology Platform for Ovarian Cancer on November 14, 2018 at 5:38 am
Precision Therapeutics’ medicine business is committed to improving the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to rich data diseases databases. […]
- A Spark Of Good News For Precision Oncology In Breast Cancer on November 14, 2018 at 2:00 am
This potentially big finding—that an AKT inhibitor extends survival in patients with metastatic breast cancer—got lost amid news about giving less treatment for early ... well past the point of thinki... […]
- Precision Medicine Has Transformed Cancer Treatment. Here’s How to Move It Beyond Oncology on November 12, 2018 at 2:24 pm
The 21st century is the century of biology, where we’re seeing tremendous discoveries in science and medicine that are improving quality of life for people around the world. We are already ... […]
- The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in Funding on November 8, 2018 at 6:01 am
Druley attributes poor outcomes in children with AML to residual cancer cells that remain after treatment. His lab is developing a strategy to sharpen molecular detection of AML and identify the preci... […]
- Regenstrief scientist calls for precision surveillance for colon cancer screening on November 7, 2018 at 11:08 pm
targeted focus of precision medicine and the application of these concepts to colon cancer screening and surveillance. "The goal of colorectal cancer surveillance is to reduce incidence and death from ... […]
- Precision medicine : Statistical model can calculate potential success of new drugs on November 7, 2018 at 5:10 pm
Researchers in precision medicine are therefore conducting clinical ... more effective than the standard treatment. For example, in cancer studies it is possible to predict in which patients ... […]
- BRIEF-Precision Therapeutics Secures Rights To Novel Technology Designed To Develop Cancer Drugs on November 6, 2018 at 2:58 pm
Nov 6 (Reuters) - Precision Therapeutics Inc: * PRECISION THERAPEUTICS SECURES RIGHTS TO NOVEL TECHNOLOGY DESIGNED TO DEVELOP DRUGS THAT TARGET SPECIFIC CANCER BY ITS MUTATION * PRECISION THERAPEUTICS ... […]
via Bing News